Roman YELENSKY,David FABRIZIO,Marcin KOWANETZ,David SHAMES,Garrett, M. FRAMPTON,Priti HEGDE,Philip, J. STEPHENS,James, Xin SUN,Wei ZOU
申请号：
MX2019003934
公开号：
MX2019003934A
申请日:
2017.10.06
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor- infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).La presente invención proporciona métodos y composiciones terapéuticos y de diagnóstico para el cáncer por ejemplo, cáncer de pulmón (por ejemplo, NSCLC), cáncer de vejiga (por ejemplo, UC), cáncer de riñón (por ejemplo, RCC), cáncer de mama (por ejemplo, TNBC) o melanoma. La invención proporciona métodos para el tratamiento del cáncer (por ejemplo, cáncer de pulmón (por ejemplo, NSCLC), cáncer de vejiga (por ejemplo, UC), cáncer de riñón (por ejemplo, RCC), cáncer de mama (por ejemplo, TNBC) o melanoma), métodos
